Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.34 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241562 | 0.86 | L3MBTL1 (0.55) | L3MBTL1 | |
| SCHEMBL9071903 | 0.86 | KMT2A (0.42) | RENTRPM8MEN1KMT2ASLC6A2 | |
| SCHEMBL2669500 | 0.86 | KMT2A (0.42) | RENTRPM8MEN1KMT2ASLC6A2 | |
| SCHEMBL1240716 | 0.81 | L3MBTL1 (0.56) | L3MBTL1TRPM8 | |
| SCHEMBL3194414 | 0.81 | L3MBTL1 (0.56) | L3MBTL1TRPM8 | |
| SCHEMBL2657776 | 0.76 | KDM4E (0.41) | L3MBTL1MEN1KMT2A | |
| SCHEMBL25030164 | 0.75 | — | — | |
| SCHEMBL25030339 | 0.74 | CYP3A4 (0.30) | — | |
| SCHEMBL12204361 | 0.73 | TRPM8 (0.39) | TRPM8KMT2ASLC6A2SLC6A4 | |
| SCHEMBL9071933 | 0.73 | MAOB (0.42) | SLC6A2SLC6A4TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362049-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-8318778-B2 | Urea glucokinase activators | NOVO NORDISK A/S (DK) | 2012-11-27 | — | — | US | disclosed |
| US-20120165375-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-20100041711-A1 | Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-2099777-A1 | UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008084044-A1 | UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041711-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | L3MBTL1 4720/4885REN 143/4885KEAP1 1091/4885 |
| US-20120165375-A1 | Urea Glucokinase Activators | GCK, GCKR, HK2 | L3MBTL1 4720/4885REN 143/4885KEAP1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.